Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. announced a manager’s transaction involving the consolidation of shares following a synthetic share repurchase plan. This consolidation, affecting shares held by Elizabeth Tallett, aligns with the terms approved by shareholders in June 2024, thus reducing the number of issued shares from 36 to 35 for every 36 held, impacting the equity structure and potentially enhancing shareholder value.
More about Qiagen
QIAGEN N.V. is a company operating in the biotechnology sector, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is listed on multiple stock exchanges including Frankfurt, NYSE, and SIX, with a market focus on enhancing the reach of its diagnostic solutions globally.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.
